COVID-19 Vaccine Results A Breakthrough Moment For BioNTech
Founder Considers Its Focus To Be Immunotherapy, Not mRNA
Executive Summary
Approval for the first-to-market COVID-19 vaccine would transform BioNTech – but major challenges in meeting global demand and for its oncology pipeline await.
You may also be interested in...
Sanofi’s Uses Latecomer COVID Data To Highlight Bigger mRNA Strategy
The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around key developments in the global biopharma industry over the past week, in this podcast version of Scrip's Five Must-Know Things.
Pfizer And BioNTech Claim COVID-19 Vaccine Success
The companies look to have secured a better than expected 90% efficacy level, but will await safety data before filing later this month.